发明专利"一种治疗脑胶质瘤的联合用药物组合物"属于生物医药技术领域， 具体地，涉及一种治疗脑胶质瘤的联合用药物组合物。 上述发明专利的获得不会对公司近期经营产生重大影响，但有利于进一步完 善公司知识产权保护体系，发挥自主知识产权的技术优势，促进技术创新，从而 提升公司核心竞争力。 特此公告。 江苏吉贝尔药业股份有限公司 关于获得发明专利的自愿性披露公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏吉贝尔药业股份有限公司（以下简称"公司"）于近日收到 2 项国家知 识产权局颁发的发明专利证书，具体如下： | 发明专利 | 专利号 | 专利 | 授权 | 专利权人 | 专利 | | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 申请日 | 公告日 | | 期限 | | | JJH201601在初发性 | | | | 首都医科大学 附属北京天坛 | 20 （ | 年 自 | | 脑胶质瘤和复发性 脑胶质瘤治疗中的 | ZL 2024 1 0179585.1 | 2 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-026 1、《与诺德基金管理有限公司签署<江苏吉贝尔药业股份有限公司以简易程 序向特定对象发行股票之附生效条件的股份认购协议的补充协议>》 表决情况：7 票同意、0 票反对和 0 票弃权。 表决结果：通过。 1 江苏吉贝尔药业股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届董事会第七次会 议（以下简称"会议"）经公司全体董事同意豁免会议通知时间要求，于 2024 年 5 月 20 日在公司会议室召开。会议应参加表决董事 7 名，实际参加表决董事 7 名。公司监事及高级管理人员列席了会议。本次会议符合《中华人民共和国公司 法》及《江苏吉贝尔药业股份有限公司章程》（以下简称"《公司章程》"）等有关 规定，会议合法有效。 二、董事会会议审议情况 会议由董事长耿仲毅先生主持，经认真审议，形成以下决议： （一）逐项审议通过《关于公司与特定对象签署附生效条 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-027 江苏吉贝尔药业股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第七次会 议（以下简称"会议"）经公司全体监事同意豁免会议通知时间要求，于 2024 年 5 月 20 日在公司会议室召开。会议应参加表决监事 3 名，实际参加表决监事 3 名。本次会议符合《中华人民共和国公司法》（以下简称"《公司法》"）及《江 苏吉贝尔药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，会议 合法有效。 表决情况：3 票同意、0 票反对和 0 票弃权。 二、监事会会议审议情况 会议由监事会主席王正先生主持，经认真审议，形成以下决议： （一）逐项审议通过《关于公司与特定对象签署附生效条件的股份认购协 议的补充协议的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理办法》及《上 海证券交易所上市公司证券发行与承销业务实施细则》等相关 ...

证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2023 年年度股东大会 会议资料 二〇二四年五月 江苏吉贝尔药业股份有限公司 2023 年年度股东大会会议资料 江苏吉贝尔药业股份有限公司 2023 年年度股东大会会议须知 为了维护公司全体股东的合法权益，确保股东大会的正常秩序和议事效 率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东大会规则》以及《江苏吉贝尔药业股份有限公司章程》等 相关规定，江苏吉贝尔药业股份有限公司（以下简称"公司"）特制定本次股 东大会会议须知： 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工 作； 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务 请出席大会的股东或其代理人及其他出席、列席人员准时到达会场签到确认参 会资格。会议开始后，会议登记应当终止，由会议主持人宣布现场出席会议的 股东和代理人人数及所持有的表决权数量； 三、会议按照会议通知上所列顺序审议、表决议案； 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会 召开前一天向大会会务组进行登记。大会主持人根据会务 ...

Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes no cash dividends, no bonus shares, and no capital reserve transfers [2][3] - The board has proposed to authorize the board to formulate a specific plan for the 2024 interim dividend, which will be reviewed at the 2023 annual shareholders' meeting [4] Group 2: Product Development and Clinical Trials - The company has developed a new diabetes drug, JJH202301, which has shown promising results in preliminary pharmacokinetic tests, significantly extending the drug's half-life and reducing metabolite production [2] - The anti-cancer drug JJH201601 has received approval for clinical trials in advanced solid tumors and is currently in Phase I clinical research [3][5] - The company has patented multiple formulations of the drug Likujun, enhancing its market protection and ensuring product quality [3] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is the leading product in this category [5] - Sales data indicates uneven development across different regions, suggesting a large untapped market nationally [5] - The company is actively promoting Likujun in oncology and other key areas, contributing to sustained growth in operating performance [4]

Investment Rating - The investment rating for the company is "Buy" with a 6-month outlook [1][17]. Core Insights - The company is actively expanding its molecular block business, enhancing front-end and back-end collaboration. The unique product, Nigulol Tablets, has strong scarcity and the sales team is gradually improving [1]. - In 2023, the company achieved a revenue of 861 million yuan, a year-on-year increase of 31.49%, and a net profit of 219 million yuan, up 41.65% year-on-year. The gross margin was 88.95% and the net margin was 25.41% [9]. - The company expects revenue growth to continue, projecting revenues of 1.07 billion yuan in 2024, 1.31 billion yuan in 2025, and 1.59 billion yuan in 2026, with corresponding net profits of 281 million yuan, 351 million yuan, and 429 million yuan respectively [17][30]. Financial Performance Summary - The company's revenue growth rates are projected at 23.80% for 2024, 22.72% for 2025, and 21.74% for 2026 [30]. - The gross margin is expected to remain stable around 88% over the forecast period [30]. - The earnings per share (EPS) are projected to be 1.49 yuan in 2024, 1.86 yuan in 2025, and 2.27 yuan in 2026 [30]. Product Performance - Nigulol Tablets generated revenue of 90 million yuan in 2023, with a year-on-year growth of 61.04% and a gross margin of 94%. The sales volume reached 32.55 million tablets, up 60.89% year-on-year [22]. - The product is recognized as a recommended domestic innovative drug for treating hypertension combined with rapid heart rate, with a significant patient population [22]. - The company’s other product, Likujun Tablets, achieved revenue of 653 million yuan in 2023, a growth of 29.91%, with a gross margin of 92.6% [28]. Innovation Pipeline - The company has advanced its innovative drug pipeline, with JJH201501 entering Phase III clinical trials and other drugs progressing through various stages of development [28]. - The global antidepressant market is expanding, with significant potential for the company's new drug developments in this area [28]. Market Position - The company is positioned well within the pharmaceutical industry, focusing on innovative drug development and expanding its market share through strategic product offerings and collaborations [1][28].

Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes not paying cash dividends or issuing bonus shares [1][2][3] - The board has proposed to authorize the formulation of a mid-year dividend plan for 2024, which will be reviewed at the 2023 annual shareholders' meeting [4] - The company emphasizes investor returns and aims to balance long-term development with reasonable returns to investors [4] Group 2: Product Development and Clinical Trials - The company has introduced a new diabetes medication, JJH202301, which has shown promising results in preliminary pharmacokinetic studies, indicating a significant extension of the drug's half-life and reduced metabolite production [2][3] - The anti-cancer drug JJH201601 has received approval for clinical trials and is currently in Phase I studies, with multiple dosage groups already enrolled [3][5] - The company has patented multiple formulations of its existing drug, Likujun, to enhance product quality and clinical efficacy, thereby reducing the risk of imitation [3][5] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is positioned as a leading product in this category [5][6] - Sales data indicates uneven development across different regions, suggesting a considerable untapped market nationally [5] - The application of Likujun in oncology has been recognized in clinical guidelines, further enhancing its market prospects [5][6]

Investment Rating - The report maintains a "Buy" rating for the company [4][12]. Core Insights - The company achieved a revenue of 861 million (up 31.49%) and a net profit attributable to the parent of 219 million (up 41.65%) in 2023. The first quarter of 2024 saw a revenue of 194 million (up 17.47%) and a net profit of 53 million (up 38.15%) [2][4]. - The company is actively advancing its new drug development, with significant progress in its core products, including the rapid growth of the anti-tumor drug and hypertension treatment [3][18]. Financial Performance - The company’s revenue and net profit forecasts for 2024-2026 are as follows: - Revenue growth rates: 24.81% in 2024, 26.13% in 2025, and 24.18% in 2026 - Net profit growth rates: 27.23% in 2024, 27.46% in 2025, and 27.66% in 2026 - Corresponding EPS: 1.47, 1.88, and 2.40 yuan per share for 2024, 2025, and 2026 respectively [4][5]. - The company’s financial data shows a significant increase in revenue from 654.73 million in 2022 to 860.93 million in 2023, with projections of 1,074.49 million in 2024 [5][22]. Product Performance - The main product, Likujun tablets, generated a revenue of 653 million (up 29.91%) in 2023. The hypertension drug, Niqunlor tablets, achieved a revenue of 90 million (up 61.04%) [10][18]. - Other products also showed growth, with Yipingfeng capsules increasing by 77.95% and vinegar chlorofenac enteric-coated tablets decreasing by 8.08% [10].

关于江苏吉贝尔药业股份有限公司 以简易程序向特定对象发行股票 审核中心意见落实函的回复 保荐机构（主承销商） | | | （成都市青羊区东城根上街95号） 二〇二四年四月 上海证券交易所： 国金证券股份有限公司（以下简称"保荐机构""国金证券"）作为江苏吉贝 尔药业股份有限公司（以下简称"吉贝尔""公司"或"发行人"）以简易程序向 特定对象发行股票的保荐机构（主承销商），会同相关各方，对贵所落实意见中 所提及的相关问题进行了认真核查，并出具本回复，请贵所予以审核。（如未经 说明，本回复中的简称与募集说明书中的简称具有相同含义。） 问题 1、关于本次募投项目 根据申报材料：（1）本次募投新药研发项目与前次募投中均包括 JJH201501 Ⅲ期临床研究。前次募投项目中"国家一类抗抑郁新药（JJH201501）、国家一 类抗肿瘤新药（JJH201601）研发与试验项目"的内容包括对沃替西汀衍生物 （JJH201501）开展Ⅰ至Ⅲ期临床试验；本次募投项目 JJH201501 研发项目拟 投向 JJH201501 的Ⅲ期临床研究 10,000.00 万元；2）报告期各期末，发行人的 资产负债率分别为 9.78%、11. ...

根据申报材料：（1）本次募投新药研发项目与前次募投中均包括 JJH201501Ⅲ期临 床研究。前次募投项目中"国家一类抗抑郁新药（JJH201501）、国家一类抗肿瘤新药 （JJH201601）研发与试验项目"的内容包括对沃替西汀衍生物（JJH201501）开展Ⅰ至 Ⅲ期临床试验；本次募投项目 JJH201501 研发项目拟投向 JJH201501 的Ⅲ期临床研究 10,000.00 万元；2）报告期各期末，发行人的资产负债率分别为 9.78%、11.57%、13.76%、 12.98%。 请发行人：（1）结合招股说明书披露的前次募投项目中 JJH201601、JJH201501 的 项目投资情况、研发进展及募集资金使用情况，说明 JJH201501 研发项目（Ⅲ期临床研 究）本次募投项目与前次募投项目投资金额存在差异的合理性，本次募集说明书与招股 说明书等申报文件信息披露是否存在不一致；（2）结合本次募投项目中 JJH201501 研发 项目（Ⅲ期临床研究）与前次募投相关项目的区别与联系，说明本次募集资金继续投向 前次募投项目的必要性；如不能充分说明必要性，发行人应按照再融资监管要求合理确 定本次募投项目融 ...